Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expr...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300396 |
id |
doaj-268aaa1355464350a8486123556bc6b4 |
---|---|
record_format |
Article |
spelling |
doaj-268aaa1355464350a8486123556bc6b42020-11-24T23:48:03ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012016-01-013C10.1038/mtm.2016.81Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9Jonathan Dashkoff0Eli P Lerner1Nhi Truong2Jacob A Klickstein3Zhanyun Fan4Dakai Mu5Casey A Maguire6Bradley T Hyman7Eloise Hudry8Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USADepartment of Neurology, The Massachusetts General Hospital, and NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, The Massachusetts General Hospital, and NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAThe capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expression in nontarget cells or organs. To refine this approach, the present study characterizes the transduction profiles of new self-complementary AAV9 (scAAV9) expressing the green fluorescent protein (GFP) either under an astrocyte (glial fibrillary acidic (GFA) protein) or neuronal (Synapsin (Syn)) promoter, after intravenous injection of adult mice (2 × 1013 vg/kg). ScAAV9-GFA-GFP and scAAV9-Syn-GFP robustly transduce astrocytes (11%) and neurons (17%), respectively, without aberrant expression leakage. Interestingly, while the percentages of GFP-positive astrocytes with scAAV9-GFA-GFP are similar to the performances observed with scAAV9-CBA-GFP (broadly active promoter), significant higher percentages of neurons express GFP with scAAV9-Syn-GFP. GFP-positive excitatory as well as inhibitory neurons are observed, as well as motor neurons in the spinal cord. Additionally, both activated (GFAP-positive) and resting astrocytes (GFAP-negative) express the reporter gene after scAAV9-GFA-GFP injection. These data thoroughly characterize the gene expression specificity of AAVs fitted with neuronal and astrocyte-selective promoters after intravenous delivery, which will prove useful for central nervous system (CNS) gene therapy approaches in which peripheral expression of transgene is a concern.http://www.sciencedirect.com/science/article/pii/S2329050117300396 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jonathan Dashkoff Eli P Lerner Nhi Truong Jacob A Klickstein Zhanyun Fan Dakai Mu Casey A Maguire Bradley T Hyman Eloise Hudry |
spellingShingle |
Jonathan Dashkoff Eli P Lerner Nhi Truong Jacob A Klickstein Zhanyun Fan Dakai Mu Casey A Maguire Bradley T Hyman Eloise Hudry Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 Molecular Therapy: Methods & Clinical Development |
author_facet |
Jonathan Dashkoff Eli P Lerner Nhi Truong Jacob A Klickstein Zhanyun Fan Dakai Mu Casey A Maguire Bradley T Hyman Eloise Hudry |
author_sort |
Jonathan Dashkoff |
title |
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 |
title_short |
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 |
title_full |
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 |
title_fullStr |
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 |
title_full_unstemmed |
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 |
title_sort |
tailored transgene expression to specific cell types in the central nervous system after peripheral injection with aav9 |
publisher |
Elsevier |
series |
Molecular Therapy: Methods & Clinical Development |
issn |
2329-0501 |
publishDate |
2016-01-01 |
description |
The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expression in nontarget cells or organs. To refine this approach, the present study characterizes the transduction profiles of new self-complementary AAV9 (scAAV9) expressing the green fluorescent protein (GFP) either under an astrocyte (glial fibrillary acidic (GFA) protein) or neuronal (Synapsin (Syn)) promoter, after intravenous injection of adult mice (2 × 1013 vg/kg). ScAAV9-GFA-GFP and scAAV9-Syn-GFP robustly transduce astrocytes (11%) and neurons (17%), respectively, without aberrant expression leakage. Interestingly, while the percentages of GFP-positive astrocytes with scAAV9-GFA-GFP are similar to the performances observed with scAAV9-CBA-GFP (broadly active promoter), significant higher percentages of neurons express GFP with scAAV9-Syn-GFP. GFP-positive excitatory as well as inhibitory neurons are observed, as well as motor neurons in the spinal cord. Additionally, both activated (GFAP-positive) and resting astrocytes (GFAP-negative) express the reporter gene after scAAV9-GFA-GFP injection. These data thoroughly characterize the gene expression specificity of AAVs fitted with neuronal and astrocyte-selective promoters after intravenous delivery, which will prove useful for central nervous system (CNS) gene therapy approaches in which peripheral expression of transgene is a concern. |
url |
http://www.sciencedirect.com/science/article/pii/S2329050117300396 |
work_keys_str_mv |
AT jonathandashkoff tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT eliplerner tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT nhitruong tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT jacobaklickstein tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT zhanyunfan tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT dakaimu tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT caseyamaguire tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT bradleythyman tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 AT eloisehudry tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9 |
_version_ |
1725487500923764736 |